Jernej Godec is a Principal at Atlas Venture where he focuses on finding innovative technologies and building impactful therapeutics companies to address significant medical gaps. Prior to joining Atlas, he was a senior associate at Apple Tree Partners in New York City. In that role, he worked on investments across therapeutics areas and companies with a focus on early stage technologies and company formation. Jernej completed his doctorate in immunology at Harvard University. He was jointly mentored by Arlene Sharpe and Nicholas Haining, where he studied how co-inhibitory receptors and transcriptional programs orchestrate differentiation of cytotoxic T lymphocytes and published in top peer-reviewed journals.